GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (OTCPK:LBPWQ) » Definitions » ROCE %

4d pharma (4d pharma) ROCE % : -192.14% (As of Dec. 2021)


View and export this data going back to 2021. Start your Free Trial

What is 4d pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. 4d pharma's annualized ROCE % for the quarter that ended in Dec. 2021 was -192.14%.


4d pharma ROCE % Historical Data

The historical data trend for 4d pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma ROCE % Chart

4d pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROCE %
Get a 7-Day Free Trial -30.81 -41.28 -83.27 -110.72 -168.88

4d pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -101.04 -102.51 -96.96 -105.33 -192.14

4d pharma ROCE % Calculation

4d pharma's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=-75.605/( ( (47.609 - 8.672) + (57.101 - 6.503) )/ 2 )
=-75.605/( (38.937+50.598)/ 2 )
=-75.605/44.7675
=-168.88 %

4d pharma's ROCE % of for the quarter that ended in Dec. 2021 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2021 )  (Q: Jun. 2021 )(Q: Dec. 2021 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2021 )  (Q: Jun. 2021 )(Q: Dec. 2021 )
=-103.328/( ( (66.826 - 9.868) + (57.101 - 6.503) )/ 2 )
=-103.328/( ( 56.958 + 50.598 )/ 2 )
=-103.328/53.778
=-192.14 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2021) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4d pharma  (OTCPK:LBPWQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


4d pharma ROCE % Related Terms

Thank you for viewing the detailed overview of 4d pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


4d pharma (4d pharma) Business Description

Traded in Other Exchanges
N/A
Address
9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

4d pharma (4d pharma) Headlines